Cysteamine Hydrochloride for nephropathic Cystinosis, open-label Phase III pivotal study

Trial Profile

Cysteamine Hydrochloride for nephropathic Cystinosis, open-label Phase III pivotal study

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs Mercaptamine (Primary)
  • Indications Nephropathic cystinosis
  • Focus Registrational; Therapeutic Use
  • Acronyms Cystadrops09choc-study
  • Sponsors Orphan Europe
  • Most Recent Events

    • 07 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top